"Rescue" regimens after Helicobacter pylori treatment failure

World Journal of Gastroenterology

Volumn 14, Issue 35, 2008, Pages 5385-5402

  Gisbert, Javier P ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Helicobacter pylori; Levofloxacin; Rescue; Rifabutin; Salvage

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH; BISMUTH CITRATE; CLARITHROMYCIN; ESOMEPRAZOLE; FURAZOLIDONE; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; NITROIMIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; RANITIDINE BISMUTH CITRATE; RIFABUTIN; TETRACYCLINE; TINIDAZOLE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BONE MARROW TOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERADICATION THERAPY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HUMAN; LEUKOPENIA; TENDINITIS; TENDON RUPTURE; THROMBOCYTOPENIA; DRUG EFFECT; HELICOBACTER PYLORI; MICROBIOLOGICAL EXAMINATION; REVIEW; SALVAGE THERAPY; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROBIAL SENSITIVITY TESTS; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 64849083887     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.5385     Document Type: Article

References (190)

1. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2330-2338
2. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180
3. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781
4. Gisbert JP, Gonzalez L, Calvet X, Garcia N, Lopez T, Roque M, Gabriel R, Pajares JM. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 1319-1328
5. Gisbert JP, Pajares R, Pajares JM. Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter 2007; 12 Suppl 2: 50-58
6. Hawkey CJ, Atherton JC, Treichel HC, Thjodleifsson B, Ravic M. Safety and efficacy of 7-day rabeprazole-and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. Aliment Pharmacol Ther 2003; 17: 1065-1074
7. Paoluzi P, Iacopini F, Crispino P, Nardi F, Bella A, Rivera M, Rossi P, Gurnari M, Caracciolo F, Zippi M, Pica R. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study. Helicobacter 2006; 11: 562-568
8. Veldhuyzen Van Zanten S, Machado S, Lee J. One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 1381-1387
9. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004; 20: 99-107
10. Laine L, Fennerty MB, Osato M, Sugg J, Suchower L, Probst P, Levine JG. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol 2000; 95: 3393-3398
11. Laine L, Suchower L, Frantz J, Connors A, Neil G. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. Am J Gastroenterol 1998; 93: 2106-2112
12. Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol 2005; 100: 1696-1701
13. Gisbert JP, Dominguez-Munoz A, Dominguez-Martin A, Gisbert JL, Marcos S. Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? Am J Gastroenterol 2005; 100: 1935-1940
14. Della Monica P, Lavagna A, Masoero G, Lombardo L, Crocella L, Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002; 16: 1269-1275
15. Altintas E, Sezgin O, Ulu O, Aydin O, Camdeviren H. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol 2004; 10: 1656-1658
16. Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, Gursoy M, Gur G, Yilmaz U, Boyacioglu S. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol 2004; 10: 668-671
17. Vakil N, Hahn B, McSorley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 1998; 93: 1432-1435
18. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-1384
19. Axon A. Quadruple therapy should be second-line treatment for Helicobacter pylori infection. In: Hunt RH, Tytgat GNJ, eds. Helicobacter pylori: Basic Mechanisms to Clinical Cure. London: Kluwer, 2000: 631-635
20. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002; 16: 1047-1057
21. Gisbert JP, Pajares JM. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter 2005; 10: 363-372
22. Zullo A, Hassan C, Lorenzetti R, Winn S, Morini S. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori? Dig Liver Dis 2003; 35: 357-361
23. de Boer WA, Tytgat GN. Regular review: treatment of Helicobacter pylori infection. BMJ 2000; 320: 31-34
24. Calvet X, Gene E, Sanfeliu I. [Therapeutic strategies in Helicobacter pylori infection] Med Clin (Barc) 2001; 116: 239
25. Houben MH, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 13: 1047-1055
26. Peitz U, Hackelsberger A, Malfertheiner P. A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Drugs 1999; 57: 905-920
27. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000; 45: 68-76
28. van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999; 94: 1751-1759
29. Tompkins DS, Perkin J, Smith C. Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. Helicobacter 1997; 2: 185-187
30. Parente F, Cucino C, Bianchi Porro G. Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts. Dig Liver Dis 2003; 35: 523-528
31. Battaglia G, Di Mario F, Vigneri S, Vianello F, Benvenuti ME, Donisi PM, Stracca-Pansa V, Pasquino M. Strategy for the retreatment of failed Helicobacter pylori eradication therapy: a case series. Ital J Gastroenterol Hepatol 1998; 30: 370-374
32. Deltenre M, Ntounda R, Jonas C, De Koster E. Eradication of Helicobacter pylori: why does it fail? Ital J Gastroenterol Hepatol 1998; 30 Suppl 3: S326-S328
33. Kobayashi I, Saika T, Muraoka H, Murakami K, Fujioka T. Helicobacter pylori isolated from patients who later failed H. pylori eradication triple therapy readily develop resistance to clarithromycin. J Med Microbiol 2006; 55: 737-740
34. Yahav J, Samra Z, Niv Y, Evans CT, Passaro DJ, Dinari G, Shmuely H. Susceptibility-guided vs. empiric retreatment of Helicobacter pylori infection after treatment failure. Dig Dis Sci 2006; 51: 2316-2321
35. Lamouliatte H, Megraud F, Delchier JC, Bretagne JF, Courillon-Mallet A, De Korwin JD, Fauchere JL, Labigne A, Flejou JF, Barthelemy P. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003; 18: 791-797
36. Avidan B, Melzer E, Keller N, Bar-Meir S. The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication. Isr Med Assoc J 2001; 3: 163-165
37. Miwa H, Nagahara A, Kurosawa A, Ohkusa T, Ohkura R, Hojo M, Enomoto N, Sato N. Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther 2003; 17: 1545-1551
38. Shimoyama T, Fukuda S, Mikami T, Fukushi M, Munakata A. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. J Gastroenterol 2004; 39: 927-930
39. Nagahara A, Miwa H, Kawabe M, Kurosawa A, Asaoka D, Hojo M, Iijima K, Terai T, Ohkusa T, Miyazaki A, Sato N. Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen. J Gastroenterol 2004; 39: 1051-1055
40. Murakami K, Okimoto T, Kodama M, Sato R, Watanabe K, Fujioka T. Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection. J Clin Gastroenterol 2008; 42: 139-142
41. Shirai N, Sugimoto M, Kodaira C, Nishino M, Ikuma M, Kajimura M, Ohashi K, Ishizaki T, Hishida A, Furuta T. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol 2007; 63: 743-749
42. Isomoto H, Inoue K, Furusu H, Enjoji A, Fujimoto C, Yamakawa M, Hirakata Y, Omagari K, Mizuta Y, Murase K, Shimada S, Murata I, Kohno S. High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 18: 101-107
43. Murakami K, Okimoto T, Kodama M, Sato R, Miyajima H, Ono M, Inoue K, Watanabe K, Otsu S, Fujioka T. Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection. Helicobacter 2006; 11: 436-440
44. Matsuhisa T, Kawai T, Masaoka T, Suzuki H, Ito M, Kawamura Y, Tokunaga K, Suzuki M, Mine T, Takahashi S, Sakaki N. Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area. Helicobacter 2006; 11: 152-158
45. Gisbert JP, Boixeda D, Bermejo F, Nieves Rincon M, Jesus Higes M, Angeles Arpa M, Garcia Arata I, Martin de Argila C, Garcia Plaza A. Re-treatment after Helicobacter pylori eradication failure. Eur J Gastroenterol Hepatol 1999; 11: 1049-1054
46. Perri F, Villani MR, Quitadamo M, Annese V, Niro GA, Andriulli A. Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? Aliment Pharmacol Ther 2001; 15: 1017-1022
47. Nagahara A, Miwa H, Ohkura R, Yamada T, Sato K, Hojo M, Sato N. Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2001; 16: 613-618
48. European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8-13
49. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 1-12
50. Gisbert JP, Calvet X, Gomollon F, Sainz R. [Treatment for the eradication of Helicobacter pylori. Recommendations of the Spanish Consensus Conference] Med Clin (Barc) 2000; 114: 185-195
51. Baena Diez JM, Lopez Mompo C, Rams Rams F, Garcia Lareo M, Rosario Hernandez Ibanez M, Teruel Gila J. [Efficacy of a multistep strategy for Helicobacter pylori eradication: quadruple therapy with omeprazole, metronidazole, tetracycline and bismuth after failure of a combination of omeprazole, clarithromycin and amoxycillin] Med Clin (Barc) 2000; 115: 617-619
52. Bilardi C, Dulbecco P, Zentilin P, Reglioni S, Iiritano E, Parodi A, Accornero L, Savarino E, Mansi C, Mamone M, Vigneri S, Savarino V. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2004; 2: 997-1002
53. Elizalde IR, Borda F, Jara C, Martínez A, Rodríguez C, Jiménez J. Eficacia de dos tratamientos consecutivos en la erradicación de Helicobacter pylori. Anales Sis San Navarra 1998; 21 Supl 2: 83-88
54. Choung RS, Lee SW, Jung SW, Han WS, Kim MJ, Jeen YT, Park JJ, Lee HS, Chun HJ, Um SH, Choi JH, Kim CD, Ryu HS, Hyun JH. [Comparison of the effectiveness of quadruple salvage regimen for Helicobacter pylori infection according to the duration of treatment] Korean J Gastroenterol 2006; 47: 131-135
55. Chung SJ, Lee DH, Kim N, Jung SH, Kim JW, Hwang JH, Park YS, Lee KH, Jung HC, Song IS. Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease. Hepatogastroenterology 2007; 54: 1293-1296
56. Gasbarrini A, Ojetti V, Pitocco D, Armuzzi A, Silveri NG, Pola P, Ghirlanda G, Gasbarrini G. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scand J Gastroenterol 2000; 35: 260-263
57. Gisbert JP, Gisbert JL, Marcos S, Gravalos RG, Carpio D, Pajares JM. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999; 13: 1311-1316
58. Gomollón F, Ducons JA, Ferrero M, Garcia Cabezudo J, Guirao R, Simon MA, Montoro M. Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. Helicobacter 1999; 4: 222-225
59. Lee JM, Breslin NP, Hyde DK, Buckley MJ, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999; 13: 489-496
60. Lee JH, Cheon JH, Park MJ, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS. [The trend of eradication rates of second-line quadruple therapy containing metronidazole for Helicobacter pylori infection: an analysis of recent eight years] Korean J Gastroenterol 2005; 46: 94-98
61. Marko D, Calvet X, Ducons J, Guardiola J, Tito L, Bory F. Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis. Helicobacter 2005; 10: 22-32
62. Michopoulos S, Tsibouris P, Bouzakis H, Balta A, Vougadiotis J, Broutet N, Kralios N. Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens. Aliment Pharmacol Ther 2000; 14: 737-744
63. Navarro-Jarabo JM, Fernandez N, Sousa FL, Cabrera E, Castro M, Ramirez LM, Rivera R, Ubina E, Vera F, Mendez I, Rivas-Ruiz F, Moreno JL, Perea-Milla E. Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection. BMC Gastroenterol 2007; 7: 31
64. Nista EC, Candelli M, Cremonini F, Cazzato IA, Di Caro S, Gabrielli M, Santarelli L, Zocco MA, Ojetti V, Carloni E, Cammarota G, Gasbarrini G, Gasbarrini A. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003; 18: 627-633
65. Orsi P, Pinazzi O, Aragona G, Di Mario F. Rabeprazole/Levofloxacin based triple therapy as a Salvatage Treatment after Failure of H pylori eradication with standard regimens. Helicobacter 2003; 8: 339-493
66. Perri F, Festa V, Clemente R, Villani MR, Quitadamo M, Caruso N, Bergoli ML, Andriulli A. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001; 96: 58-62
67. Perri F, Festa V, Merla A, Barberani F, Pilotto A, Andriulli A. Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2003; 18: 815-820
68. Sicilia B, Sierra E, Lago A, Villar M, Garcia S, Gomollon F. [High eradication rates in Helicobacter pylori infection in patients with duodenal ulcer who failed previous eradication therapy] Med Clin (Barc) 2000; 115: 641-643
69. Uygun A, Ozel AM, Yildiz O, Aslan M, Yesilova Z, Erdil A, Bagci S, Gunhan O. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy. J Gastroenterol Hepatol 2008; 23: 42-45
70. Wong WM, Gu Q, Lam SK, Fung FM, Lai KC, Hu WH, Yee YK, Chan CK, Xia HH, Yuen MF, Wong BC. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 553-560
71. Wu DC, Hsu PI, Chen A, Lai KH, Tsay FW, Wu CJ, Lo GH, Wu JY, Wu IC, Wang WM, Tseng HH. Randomized comparison of two rescue therapies for Helicobacter pylori infection. Eur J Clin Invest 2006; 36: 803-809
72. Beales IL. Efficacy of Helicobacter pylori eradication therapies: a single centre observational study. BMC Gastroenterol 2001; 1: 7
73. de Boer WA, Driessen WM, Potters VP, Tytgat GN. Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol 1994; 89: 1993-1997
74. Gomollón F, Valdeperez J, Garuz R, Fuentes J, Barrera F, Malo J, Tirado M, Simon MA. [Cost-effectiveness analysis of 2 strategies of Helicobacter pylori eradication: results of a prospective and randomized study in primary care] Med Clin (Barc) 2000; 115: 1-6
75. Rinaldi V, Zullo A, De Francesco V, Hassan C, Winn S, Stoppino V, Faleo D, Attili AF. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther 1999; 13: 163-168
76. Zullo A, Hassan C, Campo SM, Lorenzetti R, Febbraro I, De Matthaeis M, Porto D, Morini S. A triple therapy regimen after failed Helicobacter pylori treatments. Aliment Pharmacol Ther 2001; 15: 1193-1197
77. Gisbert JP, Fuentes J, Carpio D, Tito L, Guardiola J, Tomas A, Olivares D, Calvet X. 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2005; 21: 1249-1253
78. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001; 36: 690-700
79. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Levofloxacin- vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure. Helicobacter 2007; 12: 68-73
80. Koksal AS, Parlak E, Filik L, Yolcu OF, Odemis B, Ulker A, Sasmaz N, Ozden A, Sahin B. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients. J Gastroenterol Hepatol 2005; 20: 637-642
81. Gisbert JP, Pajares JM, Valle J. Ranitidine bismuth citrate therapy regimens for treatment of Helicobacter pylori infection: a review. Helicobacter 1999; 4: 58-66
82. Van Oijen AH, Verbeek AL, Jansen JB, De Boer WA. Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies. Aliment Pharmacol Ther 2000; 14: 991-999
83. Gisbert JP, Gonzalez L, Calvet X. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter 2005; 10: 157-171
84. Thong-Ngam D, Mahachai V. 14-day quadruple therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure in Thailand. J Med Assoc Thai 2006; 89 Suppl 3: S119-S125
85. Kearney DJ. Retreatment of Helicobacter pylori infection after initial treatment failure. Am J Gastroenterol 2001; 96: 1335-1339
86. Caselli M, Zullo A, Maconi G, Parente F, Alvisi V, Casetti T, Sorrentino D, Gasbarrini G. "Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis 2007; 39: 782-789
87. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 2003; 63: 2769-2802
88. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006; 101: 488-496
89. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35-44
90. Vaira D, Ricci C, Lanzini A, Perna F, Romano A, Corinaldesi R. How to proceed in Helicobacter pylori-positive chronic gastritis refractory to first- and second-line eradication therapy. Dig Dis 2007; 25: 203-205
91. Sanchez JE, Saenz NG, Rincon MR, Martin IT, Sanchez EG, Martinez MJ. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother 2000; 46: 283-285
92. Xia HH, Yu Wong BC, Talley NJ, Lam SK. Alternative and rescue treatment regimens for Helicobacter pylori eradication. Expert Opin Pharmacother 2002; 3: 1301-1311
93. Zou J, Yang ZX, Qin ZM. [Laboratory and clinical study of levofloxacin against Helicobacter pylori] Zhonghua Yixue Zazhi 2003; 83: 1778-1781
94. Gatta L, Zullo A, Perna F, Ricci C, De Francesco V, Tampieri A, Bernabucci V, Cavina M, Hassan C, Ierardi E, Morini S, Vaira D. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005; 22: 45-49
95. Antos D, Schneider-Brachert W, Bastlein E, Hanel C, Haferland C, Buchner M, Meier E, Trump F, Stolte M, Lehn N, Bayerdorffer E. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 2006; 11: 39-45
96. Kumala W, Rani A. Patterns of Helicobacter pylori isolate resistance to fluoroquinolones, amoxicillin, clarithromycin and metronidazoles. Southeast Asian J Trop Med Public Health 2006; 37: 970-974
97. Tanaka M, Isogai E, Isogai H, Hayashi S, Hirose K, Kimura K, Sugiyama T, Sato K. Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. J Antimicrob Chemother 2002; 49: 1039-1040
98. Watanabe Y, Aoyama N, Shirasaka D, Maekawa S, Kuroda K, Miki I, Kachi M, Fukuda M, Wambura C, Tamura T, Kasuga M. Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003; 35: 711-715
99. Yahav J, Shmuely H, Niv Y, Bechor J, Samra Z. In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure. Diagn Microbiol Infect Dis 2006; 55: 81-83
100. Matsumoto Y, Miki I, Aoyama N, Shirasaka D, Watanabe Y, Morita Y, Toyoda M, Mitani T, Miyachi H, Tamura T, Kasuga M. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005; 37: 821-825
101. Cammarota G, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, Gasbarrini A, Armuzzi A, Zocco MA, Santarelli L, Arancio F, Gasbarrini G. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 1339-1343
102. Di Caro S, Zocco MA, Cremonini F, Candelli M, Nista EC, Bartolozzi F, Armuzzi A, Cammarota G, Santarelli L, Gasbarrini A. Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 2002; 14: 1309-1312
103. Marzio L, Coraggio D, Capodicasa S, Grossi L, Cappello G. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 2006; 11: 237-242
104. Rispo A, Di Girolamo E, Cozzolino A, Bozzi R, Morante A, Pasquale L. Levofloxacin in first-line treatment of Helicobacter pylori infection. Helicobacter 2007; 12: 364-365
105. Gisbert JP, Fernandez-Bermejo M, Molina-Infante J, Perez-Gallardo B, Prieto-Bermejo AB, Mateos-Rodriguez JM, Robledo-Andres P, Gonzalez-Garcia G. First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2007; 26: 495-500
106. Lee JH, Hong SP, Kwon CI, Phyun LH, Lee BS, Song HU, Ko KH, Hwang SG, Park PW, Rim KS, Kim S. [The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication] Korean J Gastroenterol 2006; 48: 19-24
107. Wong WM, Gu Q, Chu KM, Yee YK, Fung FM, Tong TS, Chan AO, Lai KC, Chan CK, Wong BC. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23: 421-427
108. Gisbert JP, Bermejo F, Castro-Fernandez M, Perez-Aisa A, Fernandez-Bermejo M, Tomas A, Barrio J, Bory F, Almela P, Sanchez-Pobre P, Cosme A, Ortiz V, Nino P, Khorrami S, Benito LM, Carneros JA, Lamas E, Modolell I, Franco A, Ortuno J, Rodrigo L, Garcia-Duran F, O'Callaghan E, Ponce J, Valer MP, Calvet X. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 2008; 103: 71-76
109. Giannini EG, Bilardi C, Dulbecco P, Mamone M, Santi ML, Testa R, Mansi C, Savarino V. A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication. Aliment Pharmacol Ther 2006; 23: 281-287
110. Page RL 2nd, Ferguson D, Cantu M. An alternative salvage regimen for Helicobacter pylori-resistant patients with heart failure. Cardiology 2008; 110: 112-115
111. Lee YC, Wu HM, Chen TH, Liu TY, Chiu HM, Chang CC, Wang HP, Wu MS, Chiang H, Wu MC, Lin JT. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. Helicobacter 2006; 11: 418-424
112. Kahn JB. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy 2001; 47 Suppl 3: 32-37; discussion 44-48
113. Cabrita J, Oleastro M, Matos R, Manhente A, Cabral J, Barros R, Lopes AI, Ramalho P, Neves BC, Guerreiro AS. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 2000; 46: 1029-1031
114. Miyachi H, Miki I, Aoyama N, Shirasaka D, Matsumoto Y, Toyoda M, Mitani T, Morita Y, Tamura T, Kinoshita S, Okano Y, Kumagai S, Kasuga M. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 2006; 11: 243-249
115. Bogaerts P, Berhin C, Nizet H, Glupczynski Y. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006; 11: 441-445
116. Carothers JJ, Bruce MG, Hennessy TW, Bensler M, Morris JM, Reasonover AL, Hurlburt DA, Parkinson AJ, Coleman JM, McMahon BJ. The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 2007; 44: e5-e8
117. Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, Megraud F, Sous sy CJ, Cambau E. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 2007; 29: 389-396
118. Coelho LG, Moretzsohn LD, Vieira WL, Gallo MA, Passos MC, Cindr JM, Cerqueira MC, Vitiello L, Ribeiro ML, Mendonca S, Pedrazzoli-Junior J, Castro LP. New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study. Aliment Pharmacol Ther 2005; 21: 783-787
119. Kim JM, Kim JS, Kim N, Kim SG, Jung HC, Song IS. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents 2006; 28: 6-13
120. Glocker E, Stueger HP, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 2007; 51: 346-349
121. Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D. Levofloxacin-based triple therapy for Helicobacter pylori retreatment: role of bacterial resistance. Dig Liver Dis 2007; 39: 1001-1005
122. Cammarota G, Martino A, Pirozzi G, Cianci R, Branca G, Nista EC, Cazzato A, Cannizzaro O, Miele L, Grieco A, Gasbarrini A, Gasbarrini G. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 2004; 19: 789-795
123. Zullo A, Perna F, Hassan C, Ricci C, Saracino I, Morini S, Vaira D. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther 2007; 25: 1429-1434
124. Krakowka S, Ringler SS, Eaton KA, Green WB, Leunk R. Manifestations of the local gastric immune response in gnotobiotic piglets infected with Helicobacter pylori. Vet Immunol Immunopathol 1996; 52: 159-173
125. Reilly TG, Ayres RC, Poxon V, Walt RP. Helicobacter pylori eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcer. Aliment Pharmacol Ther 1995; 9: 483-490
126. Lerang F, Moum B, Haug JB, Berge T, Tolas P, Sandvei PK, Torp R, Tonnesen T. Highly effective second-line anti-Helicobacter pylori therapy in patients with previously failed metronidazole-based therapy. Scand J Gastroenterol 1997; 32: 1209-1214
127. Magaret N, Burm M, Faigel D, Kelly C, Peterson W, Fennerty MB. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy. Dig Dis 2001; 19: 174-178
128. Axon AT. Treatment of Helicobacter pylori: an overview. Aliment Pharmacol Ther 2000; 14 Suppl 3: 1-6
129. Peitz U, Sulliga M, Wolle K, Leodolter A, Von Arnim U, Kahl S, Stolte M, Borsch G, Labenz J, Malfertheiner P. High rate of post-therapeutic resistance after failure of macrolidenitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 2002; 16: 315-324
130. Miehlke S, Hansky K, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, Kuhlisch E, Bastlein E, Jacobs E, Bayerdorffer E, Lehn N, Stolte M. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther 2006; 24: 395-403
131. Pilotto A, Franceschi M, Rassu M, Leandro G, Bozzola L, Furlan F, Di Mario F. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. Dig Liver Dis 2000; 32: 667-672
132. de Boer W, Driessen W, Jansz A, Tytgat G. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995; 345: 817-820
133. Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson SY, Kwon DH, El-Zimaity HM. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther 2000; 14: 745-750
134. Cudia B, Romano M, Gioè FP, Barbera N, Lo Gerfo D, Montalto R. "Rescue" therapy including ranitidine bismuth citrate + minocicline + amoxicillin for eradication of Helicobacter pylori in previous H.P. treatment failure. Gut 1997; 41 suppl 1: A103
135. The report of the Digestive Health Initiative SM International Update Conference on Helicobacter pylori. Gastroenterology 1997; 113: S4-S8
136. Technical annex: tests used to assess Helicobacter pylori infection. Working Party of the European Helicobacter pylori Study Group. [i Gut 1997; 41 Suppl 2: S10-S18
137. Guslandi M. Review article: alternative antibacterial agents for Helicobacter pylori eradication. Aliment Pharmacol Ther 2001; 15: 1543-1547
138. Kim JJ, Kim JG, Kwon DH. Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing. Helicobacter 2003; 8: 202-206
139. Ali' A, Menegatti M, Gatta L, Landi F, Ricci C, Acciardi C, Miglioli M, Vaira D, Holton J. A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment. Am J Gastroenterol 1999; 94: 2321-2323
140. Gomollón F, Sicilia B, Ducons JA, Sierra E, Revillo MJ, Ferrero M. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther 2000; 14: 1335-1338
141. Vicente R, Sicilia B, Gallego S, Revillo MJ, Ducons J, Gomollon F. [Helicobacter pylori eradication in patients with peptic ulcer after two treatment failures: a prospective culture-guided study] Gastroenterol Hepatol 2002; 25: 438-442
142. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin - influence on treatment outcome. Am J Gastroenterol 1998; 93: 386-389
143. Huang JQ, Hunt RH. Treatment after failure: the problem of "non-responders". Gut 1999; 45 Suppl 1: I40-I44
144. Seppala K, Kosunen TU, Nuutinen H, Sipponen P, Rautelin H, Sarna S, Hyvarinen H, Farkkila M, Miettinen TA. Cure of Helicobacter pylori infection after failed primary treatment: one-center results from 120 patients. Scand J Gastroenterol 2000; 35: 929-934
145. Treiber G, Ammon S, Malfertheiner P, Klotz U. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter 2002; 7: 225-231
146. Chan FK, Sung JJ, Suen R, Wu JC, Ling TK, Chung SC. Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. Aliment Pharmacol Ther 2000; 14: 91-95
147. Zullo A, Hassan C, De Francesco V, Lorenzetti R, Marignani M, Angeletti S, Ierardi E, Morini S. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis 2003; 35: 232-236
148. Dore MP, Marras L, Maragkoudakis E, Nieddu S, Manca A, Graham DY, Realdi G. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter 2003; 8: 307-309
149. Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003; 8: 90-94
150. Gisbert JP, Gisbert JL, Marcos S, Pajares JM. Empirical Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Dig Liver Dis 2004; 36: 7-12
151. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000; 14: 311-316
152. Bock H, Koop H, Lehn N, Heep M. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J Clin Gastroenterol 2000; 31: 222-225
153. Canducci F, Ojetti V, Pola P, Gasbarrini G, Gasbarrini A. Rifabutin-based Helicobacter pylori eradication 'rescue therapy'. Aliment Pharmacol Ther 2001; 15: 143
154. Gisbert JP, Castro-Fernandez M, Bermejo F, Perez-Aisa A, Ducons J, Fernandez-Bermejo M, Bory F, Cosme A, Benito LM, Lopez-Rivas L, Lamas E, Pabon M, Olivares D. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol 2006; 101: 243-247
155. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2006; 24: 1469-1474
156. Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008; 27: 346-354
157. Cianci R, Montalto M, Pandolfi F, Gasbarrini GB, Cammarota G. Third-line rescue therapy for Helicobacter pylori infection. World J Gastroenterol 2006; 12: 2313-2319
158. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 1333-1343
159. de Boer WA, Borody TJ. Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy. Dig Liver Dis 2000; 32: 673-675
160. Miehlke S, Kirsch C, Schneider-Brachert W, Haferland C, Neumeyer M, Bastlein E, Papke J, Jacobs E, Vieth M, Stolte M, Lehn N, Bayerdorffer E. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003; 8: 310-319
161. Chi CH, Lin CY, Sheu BS, Yang HB, Huang AH, Wu JJ. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment Pharmacol Ther 2003; 18: 347-353
162. Zullo A, Hassan C, Lorenzetti R, Morini S. Helicobacter pylori eradication: do we have another ace up our sleeve? Dig Liver Dis 2001; 33: 805-806
163. Gisbert JP. Rescue therapy with levofloxacin after multiple H. pylori treatment failures. Aliment Pharmacol Ther 2005; 22: 653-654; author reply 654-655
164. Rokkas T, Sechopoulos P, Robotis J, Pistiolas D. Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment. Am J Gastroenterol 2006; 101: 1938; author reply 1938-1938; author reply 1939
165. Akada JK, Shirai M, Fujii K, Okita K, Nakazawa T. In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657. Antimicrob Agents Chemother 1999; 43: 1072-1076
166. Heep M, Beck D, Bayerdorffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999; 43: 1497-1499
167. Brogden RN, Fitton A. Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47: 983-1009
168. Rossi G. [An update on the antibiotic therapy of tuberculosis] Recenti Prog Med 1999; 90: 241-243
169. Borody TJ, Pang G, Wettstein AR, Clancy R, Herdman K, Surace R, Llorente R, Ng C. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23: 481-488
170. Gonzalez Carro P, Perez Roldan F, De Pedro Esteban A, Legaz Huidobro ML, Soto Fernandez S, Roncero Garcia Escribano O, Esteban Lopez-Jamar JM, Pedraza Martin C, Ruiz Carrillo F. Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments. J Gastroenterol Hepatol 2007; 22: 60-63
171. Toracchio S, Capodicasa S, Soraja DB, Cellini L, Marzio L. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig Liver Dis 2005; 37: 33-38
172. Van der Poorten D, Katelaris PH. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther 2007; 26: 1537-1542
173. Perri F, Festa V, Andriulli A. Treatment of antibiotic-resistant Helicobacter pylori. N Engl J Med 1998; 339: 53
174. Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, Oakes R, Wilson S, Roalfe A, Bennett C, Forman D. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006; CD002096
175. Xiao SD, Liu WZ, Xia DH, Jiang SJ, Wang RN, Zhang ZH, Xu WW. The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with Helicobacter (Campylobacter) pylori-a randomized double-blind placebo-controlled clinical trial. Hepatogastroenterology 1990; 37: 503-506
176. Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 1990; 34: 1637-1641
177. Kwon DH, Lee M, Kim JJ, Kim JG, El-Zaatari FA, Osato MS, Graham DY. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance. Antimicrob Agents Chemother 2001; 45: 306-308
178. Treiber G, Wittig J, Ammon S, Walker S, van Doorn LJ, Klotz U. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 2002; 162: 153-160
179. Xiao SD, Liu WZ, Hu PJ, Ouyang Q, Wang JL, Zhou LY, Cheng NN. A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China. Aliment Pharmacol Ther 2001; 15: 81-86
180. Nijevitch AA, Shcherbakov PL, Sataev VU, Khasanov RSh, Al Khashash R, Tuygunov MM. Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy with nifuratel to furazolidone. Aliment Pharmacol Ther 2005; 22: 881-887
181. Eisig JN, Silva FM, Rodriguez TN, Hashimoto CL, Barbuti RC. A furazolidone-based quadruple therapy for Helicobacter pylori retreatment in patients with peptic ulcer disease. Clinics 2005; 60: 485-488
182. Ebrahimi-Dariani N, Mirmomen S, Mansour-Ghanaei F, Noormohammadpoor P, Sotodehmanesh R, Haghpanah B, Bahrami H. The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy. Med Sci Monit 2003; 9: PI105-PI108
183. Isakov V, Domareva I, Koudryavtseva L, Maev I, Ganskaya Z. Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther 2002; 16: 1277-1282
184. Sotoudehmanesh R, Malekzadeh R, Vahedi H, Dariani NE, Asgari AA, Massarrat S. Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen. Digestion 2001; 64: 222-225
185. Qasim A, Sebastian S, Thornton O, Dobson M, McLoughlin R, Buckley M, O'Connor H, O'Morain C. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005; 21: 91-96
186. Buzas GM, Jozan J. Nitrofuran-based regimens for the eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2007; 22: 1571-1581
187. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 134: 361-369
188. Gasbarrini A, Ojetti V, Armuzzi A, Branca G, Canducci F, Torre ES, Candelli M, Pastorelli A, Anti M, Fedeli G, Fadda G, Pola P, Gasbarrini G. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 79-83
189. Tucci A, Poli L, Caletti G. Treatment of the "ineradicable" Helicobacter pylori infection. Am J Gastroenterol 1999; 94: 1713-1715
190. Gisbert JP. [The attitude in a failure to eradicate Helicobacter pylori: surrender or fight?] Med Clin (Barc) 1998; 111: 778-782